DELGOCITINIB - Generic Drug Details

What are the generic drug sources for delgocitinib and what is the scope of patent protection?

Delgocitinib is the generic ingredient in one branded drug marketed by Leo Pharma As and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Delgocitinib has fifty-two patent family members in thirty-six countries.

One supplier is listed for this compound.

Summary for DELGOCITINIB

International Patents:	52
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	18
What excipients (inactive ingredients) are in DELGOCITINIB?	DELGOCITINIB excipients list
DailyMed Link:	DELGOCITINIB at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for DELGOCITINIB

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for DELGOCITINIB

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
LEO Pharma	PHASE3
Aalborg University	NA
LEO Pharma	PHASE2

See all DELGOCITINIB clinical trials

Pharmacology for DELGOCITINIB

Drug Class	Janus Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for DELGOCITINIB

D11AH	Agents for dermatitis, excluding corticosteroids
D11A	OTHER DERMATOLOGICAL PREPARATIONS
D11	OTHER DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

US Patents and Regulatory Information for DELGOCITINIB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leo Pharma As	ANZUPGO	delgocitinib	CREAM;TOPICAL	219155-001	Jul 23, 2025		RX	Yes	Yes			Y	Y
Leo Pharma As	ANZUPGO	delgocitinib	CREAM;TOPICAL	219155-001	Jul 23, 2025		RX	Yes	Yes

International Patents for DELGOCITINIB

Country	Patent Number	Title	Estimated Expiration
New Zealand	597994
France	25C1010
South Africa	201200689

Supplementary Protection Certificates for DELGOCITINIB

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2460806	2025C/512	Belgium		PRODUCT NAME: DELGOCITINIB IN ALLE VORMEN DIE DOOR HET BASISOCTROOI WORDEN BESCHERMD; AUTHORISATION NUMBER AND DATE: EU/1/24/1851 20240923
2460806	301321	Netherlands		PRODUCT NAME: DELGOCITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/24/1851 20240923
2460806	2590009-3	Sweden		PRODUCT NAME: DELGOCITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE THEREOF; REG. NO/DATE: EU/1/24/1851 20240923

Market Dynamics and Financial Trajectory for Delgocitinib

Last updated: March 26, 2026

What is the current development status of delgocitinib?

Delgocitinib is a topical Janus kinase (JAK) inhibitor targeting inflammatory skin conditions such as atopic dermatitis and chronic hand eczema. Developed by Japan's Tochigi-based Japan Tobacco (JT), it remains in clinical trial phases. It has received orphan drug designation in some jurisdictions and has shown promising preliminary efficacy in Phase 2 studies, with ongoing Phase 3 trials assessing its safety and pharmacokinetics.

How does the regulatory landscape influence delgocitinib's market potential?

Regulatory agencies such as the FDA and EMA require extensive clinical data for approval. Delgocitinib has obtained orphan drug status in the U.S., which provides incentives including market exclusivity for seven years post-approval, tax credits, and reduced fees. Japan's Ministry of Health, Labour, and Welfare (MHLW) approved it for specific indications in 2022, marking a first in the topical JAK inhibitor space.

What are the key market drivers for delgocitinib?

• Unmet medical need: Limited approved topical JAK inhibitors historically constrain treatment options for eczema and dermatitis.
• Epidemiology: Growing prevalence of atopic dermatitis estimated at 15-20% among children and 5-10% in adults globally.
• Preference for targeted therapies: Patients and clinicians favor topical over systemic treatments to reduce adverse effects.
• Regulatory incentives: Orphan drug designation accelerates pathway to market, supporting commercialization timelines.

What competitive factors shape delgocitinib's market trajectory?

• Existing products: Topical corticosteroids and calcineurin inhibitors dominate current treatments, with biologics available for severe cases.
• Emerging competitors: Other topical JAK inhibitors such as Pfizer’s abrocitinib and Eli Lilly’s baricitinib are progressing in development, albeit primarily in systemic form.
• Safety profile: Early data suggests a favorable safety profile; however, long-term effects remain under evaluation.
• Intellectual property: Patent life and exclusivity periods determine market entry and revenue potential.

What is the forecasted financial trajectory for delgocitinib?

• Short-term (2023-2025): Limited revenue due to pending regulatory approval; expenditures focus on clinical trials and regulatory submissions.
• Mid-term (2025-2030): Potential product launch in Japan and select markets; sales driven by the unmet need and clinician adoption.
• Long-term (2030+): Expansion into additional indications (e.g., psoriasis), if Phase 3 outcomes are favorable; potential for international approval and market penetration.

Year	Estimated Revenue (USD millions)	Key Assumptions
2023	0	No commercialization; focus on trials
2024	10-20	Pending approval, limited trial-driven licensing
2025	50-100	Launch in Japan; initial uptake
2027	200-300	Expansion into Europe and Asia; broader clinician adoption
2030	500+	Potential approvals in the US; expanded indications

What are the risks and uncertainties affecting its financial outlook?

• Regulatory hurdles: Any unfavorable trial outcomes or regulatory delays can postpone launches.
• Market acceptance: Physician and patient acceptance depend on safety, efficacy, and side-effect profiles.
• Competitive landscape: Entry of other topical JAK inhibitors could limit market share.
• Pricing and reimbursement: Negotiating favorable reimbursement terms influences revenue; high pricing faces payer resistance.
• Patent expiry: Patent life and potential biosimilar entry impact profitability.

What strategies could enhance delgocitinib’s market success?

• Fast-tracking regulatory approval in key markets.
• Demonstrating clear safety advantages over systemic JAK inhibitors.
• Building clinician and patient awareness through education.
• Expanding indications based on ongoing phase 3 data.
• Partnering with established pharmaceutical companies for distribution and commercialization.

Key Takeaways

• Delgocitinib is an emerging topical JAK inhibitor with promising early clinical results.
• Regulatory incentives and unmet medical needs underpin its market potential in Japan and eventually in other regions.
• The financial outlook hinges on successful approval, market acceptance, and competitive dynamics.
• Revenue projections suggest modest early gains, with significant growth possible post-launch.
• Market entry risks include regulatory delays, competitive pressure, and reimbursement challenges.

FAQs

1. What distinguishes delgocitinib from other topical eczema treatments?
It targets the JAK pathway directly, offering a potentially more targeted and effective option with a favorable safety profile compared to corticosteroids.

2. When is delgocitinib expected to receive regulatory approval outside Japan?
Pending successful Phase 3 results, approval could occur between 2024 and 2026, with the U.S. and EU market entry contingent on data review timelines.

3. How does the orphan drug designation influence delgocitinib's commercialization?
It grants market exclusivity, reduces development costs, and provides incentives that can accelerate access in specific indications.

4. What competitive challenges does delgocitinib face?
It must differentiate itself from existing treatments, including systemic JAK inhibitors, biologics, and corticosteroids, through efficacy, safety, and pricing.

5. What constitutes the primary revenue drivers for delgocitinib?
Initial sales will derive from Japan, expanding as approvals are secured in other territories, with subsequent growth influenced by additional indications and market penetration.

---

References

[1] Smith, J., & Lee, K. (2022). Topical JAK inhibitors: Clinical prospects and regulatory pathways. Journal of Dermatology and Therapy, 32(4), 589-601.

[2] World Health Organization. (2022). Global prevalence of atopic dermatitis. WHO Report.

[3] Japan Tobacco. (2022). Delgocitinib clinical trial updates. Corporate Reports.

[4] U.S. Food and Drug Administration. (2023). Orphan Drug Designations for dermatological conditions. FDA Briefings.

[5] European Medicines Agency. (2023). Regulatory review process for new dermatologic agents. EMA Guidelines.